Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology

Neurobiology of Disease

Volumn 79, Issue , 2015, Pages 81-99

  Vaikath, Nishant N ^a,b   Majbour, Nour K ^a,c   Paleologou, Katerina E ^d   Ardah, Mustafa T ^a   van Dam, Esther ^c   van de Berg, Wilma D J ^c   Forrest, Shelley L ^e   Parkkinen, Laura ^f   Gai, Wei Ping ^g   Hattori, Nobutaka ^h   Takanashi, Masashi ^h   Lee, Seung Jae ⁱ   Mann, David M A ^j   Imai, Yuzuru ^h   Halliday, Glenda M ^k   Li, Jia Yi ^b   El Agnaf, Omar M A ^a,l  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b LUND UNIVERSITY   (Sweden)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g FLINDERS UNIVERSITY   (Australia)

^h JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ Seoul National University College of Medicine   (South Korea)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

more..

Author keywords

Conformation specific monoclonal antibodies; Dementia with Lewy bodies; Parkinson's disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; GAMMA SYNUCLEIN; MONOCLONAL ANTIBODY; TAU PROTEIN; AMYLIN; AMYLOID BETA-PROTEIN (1-42); BETA SYNUCLEIN; ITM2B PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; SNCA PROTEIN, HUMAN; SNCB PROTEIN, HUMAN; SNCG PROTEIN, HUMAN; TUMOR PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; BRAIN HOMOGENATE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR RECOGNITION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; ALZHEIMER DISEASE; ANIMAL; BRAIN; CHEMISTRY; CLINICAL TRIAL; ESCHERICHIA COLI; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROTEIN MULTIMERIZATION;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; BETA-SYNUCLEIN; BRAIN; ESCHERICHIA COLI; GAMMA-SYNUCLEIN; ISLET AMYLOID POLYPEPTIDE; LEWY BODY DISEASE; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASM PROTEINS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; TAU PROTEINS;

EID: 84929996447     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.04.009     Document Type: Article

References (70)

1. Aasly J.O., Johansen K.K., Bronstad G., Waro B.J., Majbour N.K., Varghese S., Alzahmi F., Paleologou K.E., Amer D.A., Al-Hayani A., El-Agnaf O.M. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front. Aging Neurosci. 2014, 6:248.
2. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., Diep L., Keim P.S., Shen X., Chataway T., Schlossmacher M.G., Seubert P., Schenk D., Sinha S., Gai W.P., Chilcote T.J. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281:29739-29752.
3. Appel-Cresswell S., Vilarino-Guell C., Encarnacion M., Sherman H., Yu I., Shah B., Weir D., Thompson C., Szu-Tu C., Trinh J., Aasly J.O., Rajput A., Rajput A.H., Jon Stoessl A., Farrer M.J. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 2013, 28:811-813.
4. Ardah M.T., Paleologou K.E., Lv G., Abul Khair S.B., Kazim A.S., Minhas S.T., Al-Tel T.H., Al-Hayani A.A., Haque M.E., Eliezer D., El-Agnaf O.M. Structure activity relationship of phenolic acid inhibitors of alpha-synuclein fibril formation and toxicity. Front. Aging Neurosci. 2014, 6:197.
5. Ardah M.T., Paleologou K.E., Lv G., Menon S.A., Abul Khair S.B., Lu J.H., Safieh-Garabedian B., Al-Hayani A.A., Eliezer D., Li M., El-Agnaf O.M. Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. Neurobiol. Dis. 2015, 74:89-101.
6. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. J. Biol. Chem. 1998, 152:879-884.
7. Bae E.J., Lee H.J., Rockenstein E., Ho D.H., Park E.B., Yang N.Y., Desplats P., Masliah E., Lee S.J. Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission. J. Neurosci. Off. J. Soc. Neurosci. 2012, 32:13454-13469.
8. Burre J., Sharma M., Sudhof T.C. alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E4274-E4283.
9. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
10. Choi B.K., Choi M.G., Kim J.Y., Yang Y., Lai Y., Kweon D.H., Lee N.K., Shin Y.K. Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4087-4092.
11. Cremades N., Cohen S.I., Deas E., Abramov A.Y., Chen A.Y., Orte A., Sandal M., Clarke R.W., Dunne P., Aprile F.A., Bertoncini C.W., Wood N.W., Knowles T.P., Dobson C.M., Klenerman D. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012, 149:1048-1059.
12. Croisier E., DE M.R., Deprez M., Goldring K., Dexter D.T., Pearce R.K., Graeber M.B., Roncaroli F. Comparative study of commercially available anti-alpha-synuclein antibodies. Neuropathol. Appl. Neurobiol. 2006, 32:351-356.
13. Culvenor J.G., McLean C.A., Cutt S., Campbell B.C., Maher F., Jäkälä P., Hartmann T., Beyreuther K., Masters C.L., Li Q.X. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am. J. Pathol. 1999, 155:1173-1181.
14. Dickson D.W., Liu W., Hardy J., Farrer M., Mehta N., Uitti R., Mark M., Zimmerman T., Golbe L., Sage J., Sima A., D'Amato C., Albin R., Gilman S., Yen S.H. Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol. 1999, 155:1241-1251.
15. Duda J.E., Giasson B.I., Mabon M.E., Lee V.M., Trojanowski J.Q. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol. 2002, 52:205-210.
16. El-Agnaf O.M., Irvine G.B., Guthrie D.J. Conformations of beta-amyloid in solution. J. Neurochem. 1997, 68:437-439.
17. El-Agnaf O.M., Jakes R., Curran M.D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D., Wallace A. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 1998, 440:71-75.
18. El-Agnaf O.M., Goodwin H., Sheridan J.M., Frears E.R., Austen B.M. Improved solid-phase syntheses of amyloid proteins associated with neurodegenerative diseases 2000, Bentham Science Publishers B. V. 1st ed.
19. El-Agnaf O.M., Sheridan J.M., Sidera C., Siligardi G., Hussain R., Haris P.I., Austen B.M. Effect of the disulfide bridge and the C-terminal extension on the oligomerization of the amyloid peptide ABri implicated in familial British dementia. Biochemistry 2001, 40:3449-3457.
20. El-Agnaf O.M., Walsh D.M., Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol. 2003, 2:461-462.
21. El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., Schlossmacher M.G., Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006, 20:419-425.
22. Fagerqvist T., Lindstrom V., Nordstrom E., Lord A., Tucker S.M., Su X., Sahlin C., Kasrayan A., Andersson J., Welander H., Nasstrom T., Holmquist M., Schell H., Kahle P.J., Kalimo H., Moller C., Gellerfors P., Lannfelt L., Bergstrom J., Ingelsson M. Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation. J. Neurochem. 2013, 126:131-144.
23. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
24. Gai W.P., Power J.H., Blumbergs P.C., Culvenor J.G., Jensen P.H. Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J. Neurochem. 1999, 73:2093-2100.
25. Gai W.P., Yuan H.X., Li X.Q., Power J.T., Blumbergs P.C., Jensen P.H. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol. 2000, 166:324-333.
26. Games D., Valera E., Spencer B., Rockenstein E., Mante M., Adame A., Patrick C., Ubhi K., Nuber S., Sacayon P., Zago W., Seubert P., Barbour R., Schenk D., Masliah E. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J. Neurosci. Off. J. Soc. Neurosci. 2014, 34:9441-9454.
27. Giasson B.I., Jakes R., Goedert M., Duda J.E., Leight S., Trojanowski J.Q., Lee V.M. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J. Neurosci. Res. 2000, 59:528-533.
28. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
29. Hansson O., Hall S., Ohrfelt A., Zetterberg H., Blennow K., Minthon L., Nagga K., Londos E., Varghese S., Majbour N.K., Al-Hayani A., El-Agnaf O.M. Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res. Ther. 2014, 6:25.
30. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345:27-32.
31. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., Kremmer E., Kretzschmar H.A., Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 2000, 20:6365-6373.
32. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
33. Kovacs G.G., Wagner U., Dumont B., Pikkarainen M., Osman A.A., Streichenberger N., Leisser I., Verchère J., Baron T., Alafuzoff I., Budka H., Perret-Liaudet A., Lachmann I. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012, 124:37-50.
34. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
35. Lai Y., Kim S., Varkey J., Lou X., Song J.K., Diao J., Langen R., Shin Y.K. Nonaggregated alpha-synuclein influences SNARE-dependent vesicle docking via membrane binding. Biochemistry 2014, 53:3889-3896.
36. Lesage S., Anheim M., Letournel F., Bousset L., Honoré A., Rozas N., Pieri L., Madiona K., Dürr A., Melki R., Verny C., Brice A., FPsDGS Group G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 2013, 73:459-471.
37. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., Jensen P.H. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 2004, 279:12924-12934.
38. Luk K.C., Kehm V.M., Zhang B., O'Brien P., Trojanowski J.Q., Lee V.M. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 2012, 209:975-986.
39. Luk K.C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J.Q., Lee V.M. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
40. Martin F.L., Williamson S.J., Paleologou K.E., Allsop D., El-Agnaf O.M. Alpha-synuclein and the pathogenesis of Parkinson's disease. Protein Pept. Lett. 2004, 11:229-237.
41. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
42. Masliah E., Rockenstein E., Adame A., Alford M., Crews L., Hashimoto M., Seubert P., Lee M., Goldstein J., Chilcote T., Games D., Schenk D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005, 46:857-868.
43. Masliah E., Rockenstein E., Mante M., Crews L., Spencer B., Adame A., Patrick C., Trejo M., Ubhi K., Rohn T.T., Mueller-Steiner S., Seubert P., Barbour R., McConlogue L., Buttini M., Games D., Schenk D. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 2011, 6:e19338.
44. Mougenot A.L., Betemps D., Hogeveen K.N., Kovacs G.G., Chouaf-Lakhdar L., Milhavet O., Lehmann S., Legastelois S., Pin J.J., Baron T.G. Production of a monoclonal antibody, against human alpha-synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the alpha-synuclein locus. J. Neurosci. Methods 2010, 192:268-276.
45. O'Dowd S.T., Ardah M.T., Johansson P., Lomakin A., Benedek G.B., Roberts K.A., Cummins G., El Agnaf O.M., Svensson J., Zetterberg H., Lynch T., Walsh D.M. The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. J. Alzheimers Dis. 2013, 33:923-928.
46. O'Nuallain B., Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1485-1490.
47. Paleologou K.E., Irvine G.B., El-Agnaf O.M. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochem. Soc. Trans. 2005, 33:1106-1110.
48. Paleologou K.E., Kragh C.L., Mann D.M., Salem S.A., Al-Shami R., Allsop D., Hassan A.H., Jensen P.H., El-Agnaf O.M. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009, 132:1093-1101.
49. Parnetti L., Castrioto A., Chiasserini D., Persichetti E., Tambasco N., El-Agnaf O., Calabresi P. Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 2013, 9:131-140.
50. Parnetti L., Farotti L., Eusebi P., Chiasserini D., De Carlo C., Giannandrea D., Salvadori N., Lisetti V., Tambasco N., Rossi A., Majbour N.K., El-Agnaf O., Calabresi P. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's Disease. Front. Aging Neurosci. 2014, 6:53.
51. Perrin R.J., Payton J.E., Barnett D.H., Wraight C.L., Woods W.S., Ye L., George J.M. Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci. Lett. 2003, 349:133-135.
52. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047. (New York, NY).
53. Rockenstein E., Nuber S., Overk C.R., Ubhi K., Mante M., Patrick C., Adame A., Trejo-Morales M., Gerez J., Picotti P., Jensen P.H., Campioni S., Riek R., Winkler J., Gage F.H., Winner B., Masliah E. Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 2014, 137:1496-1513.
54. Ross O.A., Braithwaite A.T., Skipper L.M., Kachergus J., Hulihan M.M., Middleton F.A., Nishioka K., Fuchs J., Gasser T., Maraganore D.M., Adler C.H., Larvor L., Chartier-Harlin M.C., Nilsson C., Langston J.W., Gwinn K., Hattori N., Farrer M.J. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol. 2008, 63:743-750.
55. Sacino A.N., Brooks M., Thomas M.A., McKinney A.B., Lee S., Regenhardt R.W., McGarvey N.H., Ayers J.I., Notterpek L., Borchelt D.R., Golde T.E., Giasson B.I. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:10732-10737.
56. Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A., Selkoe D.J. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37:583-595.
57. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
58. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
59. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 1998, 251:205-208.
60. Tokuda T., Qureshi M.M., Ardah M.T., Varghese S., Shehab S.A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M., El-Agnaf O.M. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
61. Tran H.T., Chung C.H., Iba M., Zhang B., Trojanowski J.Q., Luk K.C., Lee V.M. α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration. Cell Rep. 2014, 7:2054-2065.
62. Volpicelli-Daley L.A., Luk K.C., Patel T.P., Tanik S.A., Riddle D.M., Stieber A., Meaney D.F., Trojanowski J.Q., Lee V.M. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72:57-71.
63. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., Teplow D.B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 1997, 272:22364-22372.
64. Wang L., Das U., Scott D.A., Tang Y., McLean P.J., Roy S. alpha-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol. 2014, 24:2319-2326.
65. Waxman E.A., Duda J.E., Giasson B.I. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 2008, 116:37-46.
66. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., Aigner S., Hetzer C., Loher T., Vilar M., Campioni S., Tzitzilonis C., Soragni A., Jessberger S., Mira H., Consiglio A., Pham E., Masliah E., Gage F.H., Riek R. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
67. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., Biere A.L. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 1999, 274:19509-19512.
68. Yu S., Li X., Liu G., Han J., Zhang C., Li Y., Xu S., Liu C., Gao Y., Yang H., Uéda K., Chan P. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 2007, 145:539-555.
69. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Gomez Tortosa E., del Ser T., Muñoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
70. Zhang H., Griggs A., Rochet J.C., Stanciu L.A. In vitro study of alpha-synuclein protofibrils by cryo-EM suggests a Cu(2+)-dependent aggregation pathway. Biophys. J. 2013, 104:2706-2713.